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Background: In recent years, several oral antidiabetic drugs with new mechanisms of action have become
available, expanding the number of treatment options. Sodium/glucose cotransporter-2 (SGLT2) inhibitors are a new
class of oral antidiabetic drugs with an insulin-independent mechanism promoting urinary glucose excretion. We report
the results of a combined Phase 2 and 3 clinical study (Japic CTI-101349) of the SGLT2 inhibitor tofogliflozin (CSG452,
RG7201) in Japanese patients with type 2 diabetes mellitus.
Methods: The efficacy and safety of tofogliflozin were assessed in this multicenter, placebo-controlled, randomized,
double-blind parallel-group study involving 230 patients with type 2 diabetes mellitus with inadequate glycemic
control on diet/exercise therapy. Between 30 October 2010 and 28 February 2012, patients at 33 centers were
randomized to either placebo (n = 56) or tofogliflozin (10, 20, or 40 mg; n = 58 each) orally, once daily for 24 weeks.
The primary efficacy endpoint was the change from baseline in HbA1c at week 24.
Results: Overall, 229 patients were included in the full analysis set (placebo: n = 56; tofogliflozin 10 mg: n = 57;
tofogliflozin 20 and 40 mg: n = 58 each). The least squares (LS) mean change (95% confidence interval) from baseline
in HbA1c at week 24 was −0.028% (−0.192 to 0.137) in the placebo group, compared with −0.797% (−0.960 to −0.634)
in the tofogliflozin 10 mg group, −1.017% (−1.178 to −0.856) in the tofogliflozin 20 mg group, and −0.870% (−1.031
to −0.709) in the tofogliflozin 40 mg group (p < 0.0001 for the LS mean differences in all tofogliflozin groups vs
placebo). There were also prominent decreases in fasting blood glucose, 2-h postprandial glucose, and body weight in
all tofogliflozin groups compared with the placebo group. The main adverse events were hyperketonemia, ketonuria,
and pollakiuria. The incidence of hypoglycemia was low. Furthermore, most adverse events were classified as mild
or moderate in severity.
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Conclusions: Tofogliflozin 10, 20, or 40 mg administered once daily as monotherapy significantly decreased HbA1c and
body weight, and was generally well tolerated in Japanese patients with type 2 diabetes mellitus. Phase 3 studies were
recently completed and support the findings of this combined Phase 2 and 3 study.
Trial registration: This study was registered in the JAPIC clinical trials registry (ID: Japic CTI-101349).
Keywords: SGLT2 inhibitor, Tofogliflozin, CSG452, RG7201, HbA1c, Body weightIntroduction
In recent years, antidiabetic drugs with new mechanisms
of action have become available, expanding the treat-
ment options [1]. Some antidiabetic drugs, such as insu-
lin, sulfonylureas, and glinides, are associated with
relatively high rates of hypoglycemia that may limit their
use in some patients [2]. In addition, insulin secreta-
gogues may cause weight gain, which can exacerbate in-
sulin resistance. Even in patients who achieve good
glycemic control with antidiabetic drugs as monotherapy
or combination therapy, the pathological progression of
diabetes may lead to a gradual worsening of glycemic
control, and further increases in the doses of the antidia-
betic drug(s) may not allow the patient to regain
glycemic control [1]. Finally, many classes of antihyper-
glycemic agents are directly or indirectly reliant on insu-
lin, with the main exceptions being metformin, amylin
mimetics, and α-glucosidase inhibitors [2]. Therefore,
there is a need for new insulin-independent antidiabetic
drugs that have a low risk of hypoglycemia, do not in-
crease body weight, and improve the clinical features of
diabetes mellitus.
Sodium/glucose cotransporter-2 (SGLT2) inhibitors
represent a novel class of antidiabetic drugs that might
satisfy these requirements. Inhibition of SGLT2 repre-
sents a new mechanism of action because it reduces
blood glucose levels by inhibiting renal glucose re-
absorption and increasing urinary excretion of excess
glucose [3]. Several members of this class of drugs were
recently approved for the treatment of type 2 diabetes,
including canagliflozin in the US, dapagliflozin in Eur-
ope, and ipragliflozin in Japan. SGLT2 inhibitors could
also be combined with currently available oral antidia-
betic drugs that have different mechanisms of action [3].
Tofogliflozin (CSG452, RG7201) is a highly selective
inhibitor SGLT2 that is under development for the treat-
ment of type 2 diabetes mellitus. As part of its develop-
ment, the Tofogliflozin 003 combined Phase 2 and 3
Study (CSG003JP) was designed to assess the efficacy
and safety of tofogliflozin in patients with type 2 diabetes
mellitus with inadequate glycemic control on diet/exer-
cise therapy using a placebo-controlled, randomized,
double-blind, parallel-group design. Efficacy was asses-
sed based on the change in HbA1c from baseline to week
24. We also assessed the dose-dependent effects oftofogliflozin on the change in HbA1c and other second-
ary endpoints. The study was conducted in accordance with
the “Guidelines for Clinical Evaluation of Oral Hypoglycemic
Agents” in Japan for Phase 2 and 3 studies [4].
Methods
Study design
This was a multicenter, randomized, placebo-controlled,
double-blind, parallel-group study performed at 33 spe-
cialist and non-specialist hospitals and clinics spread
throughout Japan. The study was conducted in accord-
ance with the Declaration of Helsinki, Good Clinical
Practice, the International Conference on Harmoniza-
tion of Technical Requirements for Registration of Phar-
maceuticals for Human Use guidelines, and Japanese
law. The study was approved by ethics committees/insti-
tutional review boards at all of the participating institu-
tions. All patients provided informed consent prior to
being enrolled. After providing informed consent, pa-
tients underwent initial screening and those who met
the inclusion criteria were provisionally registered. Pa-
tients then entered a second screening phase and those
who still met the inclusion criteria were accepted for
final registration and were randomized at a 1:1:1:1 ratio
to the four study groups. An investigator at the registra-
tion center created and managed a random allocation
table, and confirmed that the study drugs and packaging
were indistinguishable. After confirmation of eligibility,
the patients were allocated to the study groups by
the registration center using a dynamic, minimization
method, with stratification for HbA1c (JDS units: <8.0%
or ≥8.0%) and sex. The participating clinicians at each
center gave the allocated drugs to the individual patients.
Patient allocation was managed using a central web-
based system. To further maintain blinding, investigators
were not permitted to measure urinary glucose levels or
drug concentrations. The investigator responsible for
managing the allocation table could only reveal the allo-
cations after the data had been reported. The overall
screening period was 8 weeks. Patients were then ran-
domized to receive tofogliflozin 10, 20, or 40 mg, or pla-
cebo, which were to be administered orally, once daily
before breakfast for 24 weeks after the screening period
(Figure 1). All patients took two tablets to make up the
required dose: (1) one tofogliflozin or placebo 10 or 20
Figure 1 Study design. Patients underwent initial screening tests and those who met the inclusion criteria were provisionally registered. Patients
then entered a second screening phase and those who still met the inclusion criteria were accepted for final registration and were randomized.
The overall screening period was 8 weeks. An additional visit was arranged for patients who discontinued the study.
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tablet. The tofogliflozin and placebo 10 and 20 mg tab-
lets were identical in appearance, as were the tofogliflo-
zin and placebo 40 mg tablets. For example, patients in
the 10 mg group took one tofogliflozin 10 mg tablet plus
one placebo 40 mg tablet. Visits were scheduled at
weeks 0, 4, 8, 12, 16, 20, and 24 during treatment. A visit
was also arranged at the time of discontinuation from
the study. The tests and examinations performed at each
visit are listed in Additional file 1: Table S1.
Inclusion and exclusion criteria
Patients were aged 20–74 years and had been diagnosed
with type 2 diabetes mellitus. Patients were included if
they met the following criteria: (1) treatment with diet
and exercise therapy only for ≥8 weeks before screening
for provisional registration; (2) HbA1c at screening
of ≥7.3 to <10.3% (National Glycohemoglobin Standardi-
zation Program [NGSP] values) and body mass index
(BMI) at screening of ≥18.5 to <45.0 kg/m2; (3) percent
changes in HbA1c (% change in Japan Diabetes Society
[JDS] units, values presented in text are NGSP units)
and body weight from the provisional registration visit
to the final registration visit of ≤10% and <5%, respect-
ively; (4) controlled blood pressure and, in patients who
were concomitantly using antihypertensive drugs, only
patients who did not need to change their dosing regi-
mens. Patients using other antidiabetic drugs were eli-
gible providing their prior drug was stopped ≥8 weeks
before the provisional registration. HbA1c was originally
reported in JDS units and was converted to NGSP units
using the following equation: HbA1c (NGSP) = HbA1c
(JDS value)/0.999 + 0.288.The main exclusion criteria were: (1) type 1 diabetes
mellitus; (2) acute diabetic complications (e.g., diabetic
ketoacidosis), acute coronary syndromes, stroke, or geni-
tourinary infections within 24 weeks before the screen-
ing for provisional registration; (3) dehydration requiring
hospitalization within 12 weeks before the screening
for provisional registration; and (4) severe or frequent
episodes of hypoglycemia within 4 weeks before the
screening for provisional registration. Patients with un-
controlled blood pressure, acute coronary syndrome, or
stroke, for example, were excluded to avoid potential
worsening of these conditions during treatment with an
experimental drug. Patients with a history of infection or
hypoglycemia were excluded because of the difficulty in
evaluating the safety of tofogliflozin.
Efficacy
The primary efficacy endpoint was the change from
baseline in HbA1c at week 24. If a patient did not have a
recorded HbA1c value at week 24, the last post-baseline
value measured before the scheduled visit at week 24
was used as the value at week 24 (last observation car-
ried forward [LOCF] procedure). The secondary efficacy
endpoints included the changes from baseline to week
24 for fasting plasma glucose; 2-h postprandial glucose
(after a meal tolerance test); fasting and 2-h postprandial
insulin (after a meal tolerance test); glycoalbumin; body
weight; pancreatic β cell function (homeostatic model
assessment [HOMA-β]) and insulin resistance (HOMA-
IR) and Matsuda Index; insulin, serum lipid levels (total
cholesterol, low-density lipoprotein–cholesterol (LDL-
C), high-density lipoprotein–cholesterol, and triglycerides);
adiponectin; blood pressure; and waist circumference. All
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LOCF procedure.
Safety
Safety endpoints included adverse events (AEs), which
included subjective symptoms and objective findings,
laboratory tests, physical findings, vital signs, 12-lead
electrocardiography, and self-monitored blood glucose.
Adverse events (AEs) were coded using the MedDRA
(Ver. 13.1). For AEs that occurred after administration
of study drug, the following information was recorded
by an investigator in a case report form: type of AE, de-
gree of severity, date of occurrence, date of restoration/
remission, treatment, outcome, and relationship to the
study drug (or evidence for the lack of relationship if the
study drug was not related to the event). If an investiga-
tor observed serious AEs occurring during the study or
within 2 weeks after terminating the study drug adminis-
tration, whether related to the study drug or not, they
reported the events to the sponsor or emergency center
by phone or fax as soon as possible (within 24 hours of
observing the serious AE). Adverse events for which a
causal relationship could not be ruled out were defined
as adverse drug reactions (ADRs). All instances of
hypoglycemia were reported as AEs. Hypoglycemia was
defined as either (1) signs/symptoms consistent with
hypoglycemia that resolved after ingesting food or ad-
ministration of glucagon or glucose, or (2) blood glu-
cose ≤ 50 mg/dL with or without signs/symptoms of
hypoglycemia.
Blood biochemical (including efficacy variables) and
laboratory variables were measured using standardized,
validated methods at an accredited central laboratory
(Mitsubishi Chemical Medience Corp., Tokyo, Japan).
The blood tofogliflozin concentration was measured by
Swiss BioAnalytics AG (Birsfelden, Switzerland).
Statistical analysis
For each treatment group, patient demographics are sum-
marized with appropriate descriptive statistics (means and
standard deviation [SD] for continuous variables, and
counts and percentages for categorical variables).
The sample size was calculated based on the expected
changes in HbA1c in the placebo and 20 mg tofogliflozin
groups of −0.2% and −0.7%, respectively. With a com-
mon SD of 0.75% based on the results of a prior Phase 2
study (unpublished data), 49 patients were needed per
group to show superiority of tofogliflozin over placebo
at a power of 90% and two-sided P < 0.05. With an ex-
pected dropout rate of 10%, the target sample size was
55 patients in each group.
The primary endpoint (change from baseline in HbA1c
at week 24) was analyzed using an analysis of covariance
(ANCOVA) model with treatment groups (placebo andtofogliflozin 10, 20, or 40 mg) as a fixed effect and base-
line HbA1c and gender as covariates to verify the super-
iority of tofogliflozin over placebo. To control the
overall significance level, a closed testing procedure
using the assumption of a monotonic dose-response
curve was applied. Once the superiority of tofogliflozin
40 mg over placebo was verified, tests for the superiority
of tofogliflozin 20 and 10 mg were performed. The (two-
sided) significance level for each test was 0.05. The
secondary endpoints body weight and fasting plasma
glucose (FPG) were analyzed using an ANCOVA model
with treatment groups (placebo and tofogliflozin 10, 20,
or 40 mg) as a fixed effect and the corresponding base-
line value as a covariate. Other secondary endpoints are
presented descriptively as the mean ± SD or n (%), as ap-
propriate. Continuous variables were compared using
t tests. In this article, all HbA1c results are presented
using NGSP values.
The number of patients with AEs and the number of
AEs/ADRs were tabulated by system organ class and
preferred term. Changes over time in laboratory values
are presented descriptively and laboratory variables were
studied for any abnormal changes of ≥5%.
Efficacy analyses were conducted in the full analysis
set, which was defined as all randomized patients who
received at least one dose of the study drug and had
both a baseline value and at least one post baseline value
of HbA1c. The efficacy analyses were repeated in the per-
protocol set, which was defined as all randomized patients
who completed the trial without a major protocol viola-
tion. Safety analyses were conducted in the safety analysis
set, which was defined as all randomized patients who re-
ceived at least one dose of the study drug.
Results
Patient disposition
A total of 235 Japanese patients were randomized (57 in
the placebo group, 59 in the tofogliflozin 10 mg group,
60 in the tofogliflozin 20 mg group, and 59 in the tofo-
gliflozin 40 mg group). The study was performed between
30 October 2010 (first patient enrolled) and 28 February
2012 (final visit of the last patient). Table 1 shows the
number of patients included in the safety analysis set, full
analysis set (FAS), and per-protocol set (PPS).
Table 2 shows the patient characteristics for the FAS.
The range of means (for continuous variables) or pro-
portions (for categorical variables) for key characteristics
across treatment groups was as follows. Female patients
accounted for 32.8–33.9% of all patients, the mean age
was 56.6–58.6 years, and 22.4–31.6% of patients were
aged ≥65 years. The mean body weight was 67.3–71.2
kg, and the mean BMI was 25.0–26.0 kg/m2. The mean
duration of type 2 diabetes mellitus was 6.0–6.7 years,
and 26.3–39.7% of patients had previously received
Table 1 Numbers of patients included in each analysis set, reasons for study withdrawal, and numbers of patients who
completed the study
Analysis set Placebo Tofogliflozin
10 mg 20 mg 40 mg Total
Target sample size 55 55 55 55 220
Patients enrolled 57 59 60 59 235
SAS* 56 58 58 58 230
Patients excluded from the SAS (did not take the study drug) 1 1 2 1 5
FAS† 56 57 58 58 229
Patients excluded from the FAS 0 1§ 0 0 1
PPS‡ 54 54 58 56 222
Patients excluded from the PPS 2 3 0 2 7
Administered <75% of the scheduled doses 0 0 0 1 1
Administered the study drug for <8 weeks from the start of treatment 2 2 0 1§‖ 5
Used a prohibited drug during treatment 0 1 0 1‖ 2
Study withdrawals before starting the study drug 1 1 2 1 5
Violated eligibility criteria 0 0 1 0 1
Other protocol violation 0 0 0 1 1
Patient decided to withdraw 0 1 1 0 2
Administrative/other reason 1 0 0 0 1
Study withdrawals after starting the study drug 8 4 1 4 17
Adverse event 1 2 0 3 6
Inadequate efficacy 4 0 0 0 4
Protocol violation 0 1 0 1 2
Patient did not administer the study drug/did not cooperate 2 1 0 0 3
Patient decided to withdraw 0 0 1 0 1
Other reason 1 0 0 0 1
Completers 48 54 57 54 213
*The safety analysis set was defined as all randomized patients who received at least one dose of the study drug.
†The full analysis set was defined as all randomized patients who received at least one dose of the study drug and had both a baseline value and at least one
post baseline value of HbA1c.
‡The per-protocol set defined as all randomized patients who completed the trial without a major protocol violation.
§No post-baseline HbA1c measurement.
‖This was the same patient.
Abbreviations: SAS safety analysis set, FAS full analysis set, PPS per-protocol set.
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8.34–8.45%, and the mean fasting blood glucose was
167.9–170.2 mg/dL. The patient characteristics were
generally comparable among the treatment groups.
Change in HbA1c from baseline to week 24
Table 3 presents the changes from baseline in HbA1c at
week 24. The least squares (LS) mean change (95% con-
fidence interval [CI]) in HbA1c from baseline to week 24
was significantly greater in all three tofogliflozin groups
than in the placebo group, with placebo-adjusted mean
changes of −0.769%, −0.990%, and −0.842% in the tofo-
gliflozin 10 mg, 20 mg, and 40 mg groups, respectively.
The decrease in HbA1c from baseline to week 24 was
significantly greater (P < 0.0001) in all three tofogliflozin
groups compared with the placebo group, with thetofogliflozin 20 mg group showing the greatest decrease
throughout the study (Figure 2).
Secondary endpoints
The secondary endpoints are summarized in Table 3.
The decreases in fasting blood glucose from baseline to
week 24 were significantly greater in all tofogliflozin
groups than in the placebo group, with placebo-adjusted
differences of −23.307, −27.338, and −23.766 mg/dL for
tofogliflozin 10 mg, 20 mg, and 40 mg, respectively. The
reductions in body weight were also significantly greater
in the tofogliflozin groups, with placebo-adjusted differ-
ences of −1.87, −2.50, and −2.61 kg for tofogliflozin 10
mg, 20 mg, and 40 mg, respectively. Among the tofogli-
flozin groups, the tofogliflozin 20 mg group showed the
greatest decrease in fasting blood glucose, and the
Table 2 Patient characteristics at baseline (FAS)
Placebo Tofogliflozin
10 mg 20 mg 40 mg
n 56 57 58 58
Age (years), Mean (SD) 56.8 (9.9) 58.6 (9.8) 56.6 (10.2) 57.0 (9.1)
Gender, n (%) Male 37 (66.1%) 38 (66.7%) 39 (67.2%) 39 (67.2%)
Female 19 (33.9%) 19 (33.3%) 19 (32.8%) 19 (32.8%)
Body weight (kg), Mean (SD) 71.20 (12.64) 67.26 (12.67) 68.06 (15.82) 68.72 (11.91)
BMI (kg/m2), Mean (SD) 26.00 (4.11) 25.07 (3.53) 24.99 (4.55) 25.78 (4.10)
HbA1c (%), Mean (SD) 8.41 (0.78) 8.45 (0.75) 8.34 (0.81) 8.37 (0.77)
Fasting plasma glucose (mg/dL), Mean (SD) 168.8 (24.9) 170.2 (32.4) 168.7 (29.6) 167.9 (37.0)
eGFR (mL/min/1.73 m2), Mean (SD) 83.78 (17.68) 84.90 (20.15) 86.78 (19.62) 86.00 (18.18)
Systolic blood pressure (mmHg), Mean (SD) 128.3 (13.7) 128.0 (15.6) 131.3 (12.9) 129.3 (12.5)
Diastolic blood pressure (mmHg), Mean (SD) 76.7 (11.4) 78.6 (10.6) 79.2 (11.7) 78.7 (9.0)
Duration of diabetes (years), Mean (SD) 6.0 (6.1) 6.3 (7.1) 6.4 (5.1) 6.7 (5.5)
Prior treatment of diabetes Yes 16 (28.6%) 15 (26.3%) 23 (39.7%) 16 (27.6%)
No 40 (71.4%) 42 (73.7%) 35 (60.3%) 42 (72.4%)
Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate.
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in body weight (Table 3 and Figure 3). When we divided
patients into tertiles of baseline values, the change in
fasting blood glucose from baseline to week 24 was
greater in patients with higher baseline fasting blood
glucose (Figure 4).
Other secondary endpoints
Fasting and 2-h postprandial insulin levels decreased sig-
nificantly in the tofogliflozin groups compared with the
placebo group; however, the magnitudes of the reduc-
tions were small (Table 3). Systolic and diastolic blood
pressures decreased significantly in the tofogliflozin
groups relative to the placebo group (Table 3). There
were significant improvements in high-density lipopro-
tein cholesterol and triglyceride levels in all of the tofo-
gliflozin groups. Although total cholesterol and LDL-C
levels decreased slightly in the tofogliflozin 10 and 20
mg groups, the magnitudes of the reductions were less
than those in the placebo group. However, there was a
non-significant increase in total cholesterol level and a
significant increase in LDL-C level in the tofogliflozin 40
mg group. The decrease in 2-h postprandial glucose and
waist circumference from baseline to week 24 was sig-
nificantly greater in all tofogliflozin groups than in the
placebo group.
Adverse events
Table 4 presents a summary of the AEs and ADRs, along
with AEs occurring at an incidence of ≥5% in any treat-
ment group. Hyperketonemia, ketonuria, pollakiuria,
and headache were more likely to occur in thetofogliflozin groups than in the placebo group. Dose-
dependent AEs were hyperketonemia and pollakiuria.
All events were mild, required no treatment, and re-
solved or improved, except for one event in one patient,
for which follow-up was unnecessary.
There were no deaths. However, myocardial ischemia
occurred in one patient in the tofogliflozin 40 mg group,
and this was classified as a serious ADR. The patient
had dyslipidemia, hypertension and obesity, which are
considered as risk factors for the progression of arterio-
sclerosis. However, because the event occurred during
the treatment with tofogliflozin, a causal relationship to
tofogliflozin could not be excluded. Because the patient
showed improvements in glycemic control during the
treatment with tofogliflozin, the administration of tofo-
gliflozin was continued.
Among AEs leading to discontinuation, mild vertigo in
one patient in the tofogliflozin 10 mg group and moder-
ate weight decrease in one patient in the tofogliflozin 40
mg group were classified as ADRs. Both events resolved.
The severity of AEs related to hypoglycemia was mild
or moderate, and all events resolved within a day. Urin-
ary tract and genital infections occurred in different
patients in the tofogliflozin 40 mg group (1.7%). These
infections were cystitis and vulvitis. Both events were
mild and resolved without treatment. The episode of
vulvitis was not considered related to tofogliflozin.
Laboratory variables
Table 5 presents the change from baseline to week 24 in
laboratory parameters. There were no abnormal changes
in any laboratory variable of ≥5% in any of the
Table 3 Changes in primary and secondary endpoints from baseline to week 24 and proportion of patients with target
HbA1c levels at week 24 (FAS)
Variable Placebo Tofogliflozin
10 mg 20 mg 40 mg
HbA1c (%)
N 56 57 58 58
LS mean (95% CI) −0.028 (−0.192 to 0.137) −0.797 (−0.960 to −0.634)††† −1.017 (−1.178 to −0.856)††† −0.870 (−1.031 to −0.709)†††
Placebo-adjusted difference — −0.769 −0.990 −0.842
Fasting blood glucose
(mg/dL)
N 56 57 58 58








Placebo-adjusted difference — −23.307 −27.338 −23.766
Body weight (kg)
N 56 57 58 58
LS mean (95% CI) −0.356 (−0.836 to 0.123) −2.230 (−2.704 to −1.756)††† −2.851 (−3.320 to −2.382)††† −2.971 (−3.440 to −2.502)†††
Placebo-adjusted difference — −1.87 −2.50 −2.61
Glycoalbumin (%)
N 53 55 58 58
Mean (SD) 0.19 (2.07) −3.09 (2.19)***††† −3.52 (2.84)***††† −3.01 (2.33)***†††
2-h PPG (mg/dL)
N 48 53 56 53
Mean (SD) −3.33 (47.6) −63.5 (49.0)***††† −71.0 (63.7)***††† −60.2 (47.2)***†††
Fasting insulin (μU/mL)
N 48 52 56 57
Mean (SD) −0.44 (4.59) −1.36 (2.95)** −2.12 (5.81)** −2.01 (2.80)***†
2-h postprandial insulin
(μU/mL)
N 45 50 56 54
Mean (SD) −0.26 (8.81) −4.14 (10.59)** −7.25 (13.74)***†† −5.58 (7.73)***††
HOMA-β
N 48 52 56 57
Mean (SD) −0.26 (15.62) 5.15 (13.48)** 3.97 (26.70) 2.67 (12.90)
HOMA − IR
N 48 52 56 57
Mean (SD) −0.296 (2.212) −1.136 (1.532)***† −1.469 (2.407)***† −1.345 (1.601)*** ††
Matsuda Index
N 40 45 50 49
Mean (SD) 0.434 (2.764) 2.137 (2.447)***†† 2.233 (2.339)***†† 2.351 (1.954)***†††
Serum lipids
Total cholesterol (mg/dL)
N 53 55 58 58
Mean (SD) −6.8 (26.6) −2.5 (20.6) −3.1 (28.4) 1.1 (23.8)
LDL-cholesterol (mg/dL)
N 53 55 58 58
Mean (SD) −4.3 (21.6) −2.7 (19.8) −2.2 (24.0) 4.5 (21.9)†
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Table 3 Changes in primary and secondary endpoints from baseline to week 24 and proportion of patients with target
HbA1c levels at week 24 (FAS) (Continued)
HDL-cholesterol (mg/dL)
N 53 55 58 58
Mean (SD) −0.2 (7.3) 3.3 (7.5)**† 3.9 (11.0)**† 4.5 (8.6)***††
Triglycerides (mg/dL)
N 53 55 58 58
Mean (SD) −21.5 (206.2) −20.7 (119.1) −23.9 (83.8)* −44.5 (95.1)***
Adiponectin (μg/mL)
N 53 55 58 58
Mean (SD) −0.17 (0.99) 0.71 (1.11)***††† 0.96 (1.61)***††† 0.45 (2.73)
Systolic blood pressure
(mmHg)
N 56 57 58 58
Mean (SD) −3.2 (13.1) −6.8 (13.1)*** −7.6 (11.4)*** −9.4 (11.1)***††
Diastolic blood pressure
(mmHg)
N 56 57 58 58
Mean (SD) −1.4 (9.8) −5.6 (9.8)***† −4.1 (8.4)*** −4.1 (8.3)***
Waist circumference (cm)
N 53 55 58 58
Mean (SD) 0.02 (3.95) −2.42 (3.37)***††† −2.47 (2.99)***††† −2.27 (3.22)***††
*P < 0.05, **P < 0.01, and ***P < 0.001 vs. baseline.
†P < 0.05, ††P < 0.01, and †††P < 0.001 vs. placebo.
Abbreviations: LS mean least squares mean, 95% CI 95% confidence interval, NGSP National Glycohemoglobin Standardization Program, HOMA-β Homeostatic
model assessment of β cell function, HOMA-IR Homeostatic model assessment of insulin resistance, 2-h PPG 2-hour postprandial glucose.
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http://www.cardiab.com/content/13/1/65tofogliflozin groups compared with placebo. Mean blood
urea nitrogen, total serum ketones, acetoacetic acid, β-
hydroxybutyric acid, and magnesium values increased
over time in the tofogliflozin groups but not in the pla-
cebo group, while uric acid, aspartate aminotransferase,
alanine aminotransferase, and γ-glutamyl transpeptidase
levels decreased significantly in the tofogliflozin groups
compared with the placebo group (Table 5).Figure 2 Mean change (LS mean) in HbA1c from baseline to time of v
time of visit for each treatment group (placebo, tofogliflozin 10, 20 or 40 m
HbA1c at week 24 (LS mean) and LS mean difference versus placebo are sh
95% CI were estimated using an ANCOVA model with treatment groups (p
HbA1c and gender as covariates.Discussion
In this study, we investigated the effects of tofogliflozin,
a selective SGLT2 inhibitor, on HbA1c in adults with
type 2 diabetes mellitus inadequately controlled with diet
and exercise. We observed a statistically significant de-
crease in HbA1c, the primary endpoint, with all three
doses of tofogliflozin as compared with placebo after 24
weeks of treatment. Among the tofogliflozin groups, theisit. Mean changes (LS mean and 95% CI) in HbA1c from baseline to
g) in the FAS (with LOCF) were plotted. Mean change from baseline in
own in the table below the graph. LS means, LS mean differences and
lacebo and tofogliflozin 10, 20, or 40 mg) as a fixed effect and baseline
Figure 3 Mean change (LS mean) in body weight from baseline to time of visit. Mean changes (LS mean and 95% CI) in body weight from
baseline to time of visit for each treatment group (placebo, tofogliflozin 10, 20 or 40 mg) in the FAS (with LOCF) were plotted. Mean change
from baseline in body weight at week 24 (LS mean) and LS mean difference versus placebo are shown in the table below the graph. LS means,
LS mean differences and 95% CI were estimated using an ANCOVA model with treatment groups (placebo and tofogliflozin 10, 20, or 40 mg) as
a fixed effect and baseline body weight as a covariate. Among the tofogliflozin groups, the tofogliflozin 40 mg group had the greatest decrease.
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http://www.cardiab.com/content/13/1/6520 mg dose had the greatest effect, reducing HbA1c by
1.017%. These improvements in HbA1c occurred in con-
junction with significant reductions in fasting blood glu-
cose in all three tofogliflozin groups. Fasting blood
glucose was also decreased in the two recent canagliflo-
zin studies, but showed a slight progressive decrease
after the maximal reduction was observed at weeks 4 [5]
and 6 [6]. In the present study, although the median
plasma trough concentration of tofogliflozin increased in
a dose-dependent manner (data not shown), this was
not reflected by dose-dependent changes in HbA1c or
fasting blood glucose. In a prior pharmacodynamic
study, the cumulative daily urine glucose excretion was
comparable at doses of 10, 20, or 40 mg tofogliflozin
(unpublished data). Therefore, it is likely SGLT2 inhib-
ition is saturated at tofogliflozin doses of 10 mg orFigure 4 Mean changes in fasting plasma glucose from baseline to w
in fasting blood glucose from baseline to week 24 tended to increase withabove, preventing further improvements in HbA1c and
other glycemic variables at doses exceeding 10 mg.
The decrease in body weight from baseline to week 24
ranged from 2.23 to 2.97 kg with tofogliflozin, which is
comparable to the level of weight loss seen with dapagli-
flozin after 24 weeks [7], and similar to that achieved with
glucagon-like peptide-1 analogs [8]. We also observed a
decrease in waist circumference of approximately 2 cm in
the tofogliflozin groups, suggesting that tofogliflozin may
improve metabolic disorders. Again, this decrease is simi-
lar to that observed with dapagliflozin [7].
Tofogliflozin also tended to reduce systolic and diastolic
blood pressure to a greater extent than placebo, and im-
proved high-density lipoprotein–cholesterol and triglycer-
ide levels. A slight decrease in uric acid was also observed.
The reductions in total cholesterol and LDL-C levels wereeek 24 by baseline fasting blood glucose tertile. The mean change
higher baseline fasting blood glucose tertile (T).
Table 4 Summary of adverse events and adverse drug reactions (Safety population)
Placebo Tofogliflozin
10 mg 20 mg 40 mg
n 56 58 58 58
Number of patients with AEs 25 (44.6%) 35 (60.3%) 31 (53.4%) 31 (53.4%)
Number of AEs 40 80 62 69
Number of patients with ADRs 4 (7.1%) 16 (27.6%) 15 (25.9%) 16 (27.6%)
Number of ADRs 6 24 26 24
Deaths 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Serious AEs 2 (3.6%)* 2 (3.4%)† 0 (0.0%) 3 (5.2%)‡
Serious ADRs 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7%)§
AEs leading to discontinuation 1 (1.8%) 1 (1.7%) 0 (0.0%) 2 (3.4%)
ADRs leading to discontinuation 0 (0.0%) 1 (1.7%) 0 (0.0%) 1 (1.7%)
AEs occurring in more than ≥5% of patients in any treatment groups
Infections and infestations
Nasopharyngitis 12 (21.4%) 9 (15.5%) 6 (10.3%) 6 (10.3%)
Upper respiratory tract infection 1 (1.8%) 0 (0.0%) 3 (5.2%) 2 (3.4%)
Investigations
Hyperketonemia 1 (1.8%) 2 (3.4%) 7 (12.1%) 8 (13.8%)
Ketonuria 0 (0.0%) 1 (1.7%) 3 (5.2%) 0 (0.0%)
Increased urinary β-2 microglobulin 1 (1.8%) 3 (5.2%) 0 (0.0%) 0 (0.0%)
Renal and urinary disorders
Pollakiuria 1 (1.8%) 3 (5.2%) 4 (6.9%) 6 (10.3%)
Musculoskeletal and connective tissue disorders
Back pain 3 (5.4%) 3 (5.2%) 2 (3.4%) 1 (1.7%)
Nervous system disorders
Headache 0 (0.0%) 3 (5.2%) 0 (0.0%) 1 (1.7%)
Other events of special interest in <5% of patients
Genitourinary infections
Cystitis 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7)
Vulvitis 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7)
Hypoglycemia 0 (0.0%) 1 (1.7) 0 (0.0%) 1 (1.7)
Increased urine volume 0 (0.0%) 0 (0.0%) 1 (1.7) 1 (1.7)
Volume-related events
Orthostatic hypotension 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7)
Dizziness 1 (1.8%) 2 (3.4%) 0 (0.0%) 0 (0.0%)
Postural dizziness 0 (0.0%) 1 (1.7) 1 (1.7) 0 (0.0%)
*Fibular fracture in one patient; colon and esophageal cancer in one patient.
†Meniscus disorder in one patient; unconsciousness in one patient.
‡Myocardial ischemia in one patient; gastrointestinal interstitial cancer in one patient; whiplash and contusion in one patient.
§Myocardial ischemia in one patient.
Abbreviations: AE Adverse event, ADR Adverse drug reaction.
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http://www.cardiab.com/content/13/1/65slightly smaller in the tofogliflozin groups than in the pla-
cebo group, and there was a non-significant increase in
total cholesterol level and a significant increase in LDL-C
level in the 40 mg group compared with the placebo
group. Other recent studies of canagliflozin and dapagli-
flozin have also described modest, dose-related increasesin LDL-C levels [5,6,9], suggesting SGLT2 inhibitors have
limited effects on total cholesterol or LDL-C. Taken to-
gether, these findings indicate that tofogliflozin may ameli-
orate some of the metabolic abnormalities associated with
type 2 diabetes, although prospective, long-term studies
are needed to confirm this possibility.
Table 5 Laboratory variables at baseline and change from baseline to week 24 (Safety population)
Placebo Tofogliflozin
10 mg 20 mg 40 mg
Baseline Change Baseline Change Baseline Change Baseline Change
n 56 48 58 54 58 56 58 54
Total serum ketones (μmol/L), Mean (SD) 87.4 (70.89) 29.7 (123.95) 93.2 (85.12) 45.6 (116.53)** 115.1 (144.01) 59.5 (136.24) ** 127.9 (155.47) 141.2 (253.68) ***††
Acetoacetic acid (μmol/L), Mean (SD) 26.8 (16.66) 7.1 (30.83) 29.0 (21.52) 10.7 (30.35)* 34.5 (37.49) 14.8 (32.49) ** 40.1 (40.69) 31.0 (63.09) ***††
β-HBA (μmol/L), Mean (SD) 60.7 (55.07) 22.6 (93.93) 64.3 (65.39) 34.7 (87.14)** 80.6 (107.30) 44.7 (105.67) ** 88.0 (116.29) 110.0 (194.65)***††
AST (IU/L, 37°C), Mean (SD) 26.5 (10.48) 0.1 (8.85) 25.6 (11.15) −3.2 (8.22)** 26.1 (10.04) −3.2 (8.23)** 26.6 (10.63) −3.7 (8.88)**†
ALT (IU/L, 37°C), Mean (SD) 28.6 (15.62) −0.4 (10.95) 28.7 (19.87) −6.5 (11.56)***† 30.10 (18.59) −7.7 (12.37)***†† 29.8 (17.51) −6.8 (12.91)***††
γ-GTP (IU/L, 37°C), Mean (SD) 51.3 (56.47) −3.2 (31.69) 44.2 (32.25) −9.7 (22.44) ** 52.2 (60.37) −17.0 (33.31) ***† 55.3 (89.75) −17.3 (56.53)*
BUN (mg/dL), Mean (SD) 14.8 (3.4) −0.2 (2.7) 14.9 (3.3) 1.5 (3.6) **†† 14.6 (4.2) 1.5 (4.1) **† 14.2 (3.2) 1.8 (3.5) ***††
SCr (mg/dL), Mean (SD) 0.72 (0.18) −0.02 (0.06) 0.70 (0.15) −0.00 (0.06) 0.71 (0.21) −0.02 (0.15) 0.70 (0.16) 0.02 (0.06)*††
eGFR (mL/min/1.73 m2), Mean (SD) 83.78 (17.68) 2.53 (9.10) 84.68 (20.04) 0.41 (8.48) 86.78 (19.62) 1.23 (12.89) 86.00 (18.18) −1.97 (7.97)††
Uric acid (mg/dL), Mean (SD) 5.09 (1.39) 0.10 (0.67) 4.77 (1.01) −0.30 (0.68) **†† 5.01 (1.19) −0.33 (0.78) **†† 5.14 (1.27) −0.14 (1.08)
*P < 0.05, **P < 0.01, and ***P < 0.001 vs. baseline.
†P < 0.05, ††P < 0.01, and †††P < 0.001 vs. placebo.
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http://www.cardiab.com/content/13/1/65The results of two Phase 3 studies of tofogliflozin were
jointly reported in article by Tanizawa et al. [10]. In these
studies, Japanese patients were treated with 20 or 40 mg
tofogliflozin as monotherapy or in combination with
other oral antidiabetic agents for 52 weeks. These doses
were selected based on the clinical efficacy and tolerabil-
ity of the three doses used in the present study. As in the
present study, both doses in the Phase 3 studies were well
tolerated, with a treatment discontinuation rate of <6%
over 52 weeks. The mean reductions in HbA1c were
0.67% and 0.66% in the 20 and 40 mg groups, respect-
ively, as monotherapy. In the combination study, the
mean HbA1c reduction ranged from 0.71% to 0.93%
across the subgroups by dose and background therapy.
A recent meta-analysis of 45 placebo-controlled stud-
ies and 13 active-controlled studies [11] revealed that
SGLT2 inhibitors significantly reduced HbA1c relative
to placebo (mean difference vs. placebo: 0.66%; 95%
CI −0.73 to −0.58%), although the change was similar to
that observed with other drugs (mean difference vs.
other drugs: −0.06%; 95% CI: −0.18 to 0.05%). The ana-
lysis also revealed that SGLT2 inhibitors reduced body
weight (mean difference vs. other drugs: −1.80 kg; 95%
CI −3.50 to −0.11 kg) and systolic blood pressure (mean
difference vs. other drugs: −4.45 mmHg; 95% CI: −5.73
to −3.18 mmHg). Therefore, the results of this study are
quite consistent with those reported for other SGLT2 in-
hibitors in terms of the improvements in glycemic con-
trol, body weight, and systolic blood pressure.
The main AEs were hyperketonemia, ketonuria, and
pollakiuria. The latter occurred at an incidence of ≥5%
with tofogliflozin, suggesting that appropriate fluid sup-
plementation is important. Serious AEs and AEs that led
to discontinuation occurred at similar rates in the tofo-
gliflozin and placebo groups, and did not appear to be
dose-dependent. Hypoglycemia was observed in the
tofogliflozin groups, but not in the placebo group, al-
though the relationship was not dose-dependent. How-
ever, the incidence of hyperketonemia and pollakiuria in
the tofogliflozin groups appeared to be dose-dependent.
Cystitis and vulvitis were observed in one patient each
in the tofogliflozin groups. However, both events were
classified as mild. Thus, the AE profile of tofogliflozin
was similar to that of SGLT2 inhibitors in general, as re-
ported in the earlier meta-analysis [11]. Significant de-
creases were observed in aspartate aminotransferase,
alanine aminotransferase, and γ-glutamyl transpeptidase,
suggestive of improvements in liver function during the
study, although this warrants confirmation in future
studies.
Several SGLT2 inhibitors have been developed, includ-
ing canagliflozin, dapagliflozin, ipragliflozin, and empa-
gliflozin, and some have been approved in various
regions for the treatment of type 2 diabetes (e.g.,canagliflozin in the US, dapagliflozin in Europe, and
ipragliflozin in Japan). Unlike other agents, they reduce
hyperglycemia by enhancing urinary excretion of excess
glucose. Because hypoglycemia, weight gain, and wors-
ening of glycemic control during long-term usage are of
concern in relation to many currently available antihy-
perglycemic agents [1,2], the development of SGLT2 in-
hibitors, which are not associated with hypoglycemia or
weight gain, is important.
SGLT2 is exclusively expressed in the kidneys [12,13]
and families with hereditary dysfunction in SGLT2 due
to genetic defects develop familial renal glucosuria. Al-
though up to 100 g of glucose is excreted in urine daily,
this does not prevent the majority of patients with famil-
ial glucosuria from living a normal life [14,15]. Con-
versely, mutations in the SGLT1 gene, involved in
glucose absorption in kidney and gastrointestinal tract,
may cause glucose–galactose malabsorption, character-
ized by serious diarrhea [16]. Thus, inhibition of SGLT1
may cause gastrointestinal disorders, and therefore it is
desirable to develop highly selective drugs for SGLT2
that specifically inhibit renal glucose reabsorption with-
out affecting intestinal glucose handling.
Tofogliflozin is a SGLT2 inhibitor, with 2,900-fold
greater selectivity for SGLT2 than SGLT1, and has the
highest selectivity of all clinically developed inhibitors
[17]. This potent selectivity might have contributed to
relatively few AEs in this clinical trial. Furthermore, the
reduced risk of hypoglycemia with tofogliflozin might re-
sult from its high selectivity for SGLT2, as it does not in-
hibit glucose reabsorption by SGLT1. More specifically,
in a hyperglycemic state, tofogliflozin promotes the urin-
ary excretion of excessive glucose from the glomerular
filtrate by inhibiting SGLT2, leading to a decrease in
blood glucose. Importantly, because of this high selectiv-
ity for SGLT2, glucose is reabsorbed by SGLT1 at a low
plasma glucose level, and thus tofogliflozin has low risk
of hypoglycemia, unlike other currently available type 2
diabetes medications. Although tofogliflozin promoted a
decrease in fasting blood glucose, safety issues must be
continuously and carefully monitored after product
launch. Like other SGLT2 inhibitors [18], tofogliflozin
was associated with significant reductions in body
weight compared with placebo. These body weight re-
ductions might be associated with a compensatory re-
duction of visceral fat resulting from the loss of calories
following increased urinary glucose excretion [15]. In-
deed, a dapagliflozin study suggested that the main
source of this body weight reduction is visceral fat tissue
[7]. An increase in blood ketone bodies was frequently
detected, although no clinical symptoms related to this
increase were reported. This increase in ketone levels
might be due to an increase in lipolysis and mobilization
of lipids/free fatty acids to compensate for the loss of
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http://www.cardiab.com/content/13/1/65glucose in urine. The increase in lipid metabolism might
contribute to reductions in visceral fat and body weight.
The influence of increased blood ketone bodies on the
safety of the study drug is unknown. Because the
decreases in fasting insulin levels in the tofogliflozin
groups were small, the hyperketonemia was unlikely to
be due to diabetic ketoacidosis caused by extreme insu-
lin deficiency.
There were some limitations in this study that warrant
mention. First, the number of type 2 diabetes mellitus
patients enrolled was relatively low compared with two
recent canagliflozin studies (230 vs 383 and 584) [5,6].
Second, a longer study duration might have been more
beneficial; however, the study period of 24 weeks was
longer than that of Inagaki et al. (12 weeks) [5] and simi-
lar to that of Stenlof et al. (26 weeks) [6]. In addition,
the results of two Phase 3 studies were recently re-
ported, and showed good efficacy and tolerability profiles
of 20 and 40 mg tofogliflozin as monotherapy or com-
bination therapy over 52 weeks of treatment [10]. Of
course, it will also be interesting to see the longer-term
efficacy and safety of tofogliflozin alone or in combin-
ation with other oral antidiabetic drugs, such as in the
ongoing 4-year EMPA-REG H2H-SU study, in which pa-
tients are being treated with empagliflozin or glimepiride
as an add-on to metformin [19]. Third, the study was
limited to Japanese patients treated in outpatient set-
tings, limiting its generalizability to patients in other
countries. Fourth, we did not consider the effects of
renal impairment; future studies should examine the im-
pact of renal impairment on the efficacy and safety of
tofogliflozin. Although further efficacy and safety data
are needed, because tofogliflozin acts independently
from insulin, there is little risk of increasing the burden
on the pancreas and causing hypoglycemia. Its ability to
enhance glycemic control and reduce body weight is also
clinically important. Moreover, the ability of tofogliflozin
to reduce blood pressure, improve lipid metabolism, and
reduce uric acid levels suggests that it may also help to
prevent vascular complications associated with type 2 dia-
betes mellitus. SGLT2 inhibitors may also improve hepatic
triglyceride accumulation, as observed with dapagliflozin
[7]. Further studies and real-life observation are needed to
confirm the efficacy and safety of tofogliflozin and other
SGLT2 inhibitors in clinical practice.
Conclusion
Tofogliflozin 10, 20, or 40 mg administered orally once
daily for 24 weeks significantly decreased HbA1c, fasting
blood glucose, and body weight as compared with pla-
cebo in patients with type 2 diabetes mellitus. Tofogliflo-
zin was also generally well tolerated, with predominantly
mild AEs being experienced. Considering the efficacy
and safety profile of tofogliflozin, doses of 20 or 40 mg,as used in the recent Phase 3 studies [10], might be ap-
propriate for clinical use in Japanese patients. Further
studies might be needed to confirm these findings, espe-
cially compared with other oral agents. Our results and
the results of the recent Phase 3 studies provide support
for using tofogliflozin as either monotherapy or in com-
bination with other oral antidiabetic drugs.
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